In the realm of healthcare, where precision is paramount, the accuracy of breast cancer risk models for women with a family history of the disease is a topic of critical importance. The recent Cochrane review, presented at the 2026 ASCO Annual Meeting, sheds light on the limitations of these models, leaving us with a sobering realization: the current tools, though widely used, fall short of providing the personalized risk assessments needed for informed clinical decisions. This is a significant finding, as it directly impacts the lives of women at elevated familial risk.
The review, conducted by researchers from Trinity College Dublin, St James’s Hospital, and collaborating institutions, analyzed 45 studies evaluating the performance of breast cancer risk models. Among the four models with sufficient published data - Gail Breast Cancer Risk Assessment Tool (BCRAT), Tyrer-Cuzick (IBIS), BOADICEA, and BRCAPRO - BOADICEA emerged as the most balanced performer. However, even this model's accuracy was only modest, falling short of the level needed for reliable personalization of care.
The findings are particularly striking when considering the implications for women with a family history of breast cancer. These women are frequently offered formal risk assessments to guide important clinical decisions, such as screening intensity and preventive interventions. However, the review reveals that the current models, despite their widespread use, are not sufficiently accurate to support personalized risk-based decision-making.
One of the key takeaways from this study is the need for more precise risk prediction tools. Lead author Sarah McGarrigle, MD, emphasizes that while these tools have value in supporting risk assessment, there is still a long way to go. This is a call to action for the medical community, urging them to continue striving for more accurate risk models.
The senior author, Elizabeth Connolly, MD, underscores the critical importance of accurate risk estimates in influencing decisions about screening intensity and preventive interventions. She notes that while progress has been made, more work is needed to ensure that clinicians and patients can rely on the most precise information available when making these consequential decisions.
In my opinion, this study highlights a critical gap in our current healthcare system. While the medical community has made significant strides in understanding and treating breast cancer, the lack of accurate risk models for women with a family history of the disease is a glaring oversight. This calls for a reevaluation of our approach to risk assessment and a renewed focus on developing more precise tools.
Looking ahead, the next steps should include further research into the development of more accurate risk models, particularly for women at elevated familial risk. Additionally, there is a need for increased collaboration between researchers, clinicians, and patients to ensure that the most precise information is available when making important clinical decisions. Only through a comprehensive and collaborative approach can we hope to bridge the gap between current risk models and the personalized risk assessments needed for informed healthcare decisions.
